Literature DB >> 1438162

Improved insulin stability through amino acid substitution.

D N Brems1, P L Brown, C Bryant, R E Chance, L K Green, H B Long, A A Miller, R Millican, J E Shields, B H Frank.   

Abstract

Insulin analogs designed to decrease self-association and increase absorption rates from subcutaneous tissue were found to have altered stability. Replacement of HB10 with aspartic acid increased stability while substitutions at B28 and/or B29 were either comparable to insulin or had decreased stability. The principal chemical degradation product of accelerated storage conditions was a disulfide-linked multimer that was formed through a disulfide interchange reaction which resulted from beta-elimination of the disulfides. The maintenance of the native state of insulin was shown to be important in protecting the disulfides from reduction by dithiothreitol and implicitly from the disulfide interchange reaction that occurs during storage. To understand how these amino acid changes alter chemical stability, the intramolecular conformational equilibria of each analog was assessed by equilibrium denaturation. The Gibbs free energy of unfolding was compared with the chemical stability during storage for over 20 analogs. A significant positive correlation (R2 = 0.8 and P less than 0.0005) exists between the conformational stability and chemical stability of these analogs, indicating that the chemical stability of insulin's disulfides is under the thermodynamic control of the conformational equilibria.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438162     DOI: 10.1093/protein/5.6.519

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  9 in total

1.  A cavity-forming mutation in insulin induces segmental unfolding of a surrounding alpha-helix.

Authors:  Bin Xu; Qing-Xin Hua; Satoe H Nakagawa; Wenhua Jia; Ying-Chi Chu; Panayotis G Katsoyannis; Michael A Weiss
Journal:  Protein Sci       Date:  2002-01       Impact factor: 6.725

Review 2.  Pharmacokinetic considerations of new insulin formulations and routes of administration.

Authors:  A Hoffman; E Ziv
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

3.  Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications.

Authors:  Qing-xin Hua; Satoe H Nakagawa; Wenhua Jia; Kun Huang; Nelson B Phillips; Shi-quan Hu; Michael A Weiss
Journal:  J Biol Chem       Date:  2008-03-10       Impact factor: 5.157

Review 4.  Degradative covalent reactions important to protein stability.

Authors:  D B Volkin; H Mach; C R Middaugh
Journal:  Mol Biotechnol       Date:  1997-10       Impact factor: 2.695

5.  Purification and identification of high molecular weight products formed during storage of neutral formulation of human insulin.

Authors:  Christian Fogt Hjorth; František Hubálek; Jonatan Andersson; Christian Poulsen; Daniel Otzen; Helle Naver
Journal:  Pharm Res       Date:  2015-01-14       Impact factor: 4.200

6.  Atomic force microscopy of crystalline insulins: the influence of sequence variation on crystallization and interfacial structure.

Authors:  C M Yip; M L Brader; M R DeFelippis; M D Ward
Journal:  Biophys J       Date:  1998-05       Impact factor: 4.033

7.  Chemical and thermal stability of insulin: effects of zinc and ligand binding to the insulin zinc-hexamer.

Authors:  Kasper Huus; Svend Havelund; Helle B Olsen; Marco van de Weert; Sven Frokjaer
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

8.  Processing of mutated human proinsulin to mature insulin in the non-endocrine cell line, CHO.

Authors:  S M Hunt; A S Tait; P P Gray; M J Sleigh
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

9.  Biophysical optimization of a therapeutic protein by nonstandard mutagenesis: studies of an iodo-insulin derivative.

Authors:  Vijay Pandyarajan; Nelson B Phillips; Gabriela P Cox; Yanwu Yang; Jonathan Whittaker; Faramarz Ismail-Beigi; Michael A Weiss
Journal:  J Biol Chem       Date:  2014-07-03       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.